University of Minnesota. Driven to Discover.
CDC reverse-engineers the virus for important trials of interventions.
The agency says prompt reporting is key to help figure out the cause of the mysterious limb-weakening condition.
The idea is to delink profit from the volume sold, pay for antibiotics based on their public health value, and encourage development of new antibiotics.
Fully 67.8% of patients received antibiotics for longer than recommended.
In one group, 35% scored below average for language, 10% for cognitive development, and 16% for motor development.
As many as 1,465 cases and 293 to 520 deaths from MERS-CoV may have been averted.
Ceftazidime-avibactam, meropenem-vaborbactam, and plazomicin were added as "reserve" antibiotics.
The drug was active against flu A, B, C, and D, as well as avian and swine strains.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.